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Abstract
 
The signaling lymphocytic activation molecule (SLAM)/CD150 family includes a family of
chromosome 1–encoded cell surface molecules with costimulatory functions mediated in part
by the adaptor protein SH2D1A (SLAM-associated protein, SAP). Deficiency in SH2D1A
protects mice from an experimental model of lupus, including the development of hypergam-
maglobulinemia, autoantibodies including anti–double stranded DNA, and renal disease. This
protection did not reflect grossly defective T or B cell function per se because SH2D1A-deficient
mice were susceptible to experimental autoimmune encephalomyelitis, a T cell–dependent disease,
and they were capable of mounting normal T-independent antigen-specific immunoglobulin
responses. Instead, T-dependent antibody responses were impaired in SH2D1A-deficient mice,
reflecting defective germinal center formation. These findings demonstrate a specific role for
the SLAM–SH2D1A system in the regulation of T-dependent humoral immune responses,
implicating members of the CD150–SH2D1A family as targets in the pathogenesis and therapy
of antibody-mediated autoimmune and allergic diseases.
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Introduction
 
The signaling lymphocytic activation molecule (SLAM)/
CD150 family includes several CD2-like cell surface glyco-
proteins encoded on chromosome 1 of both mouse and
human, including at least CD84, CD150/SLAM, CD229
(Ly-9), CD244 (2B4), and NTB-A (Ly-108). Collectively,
these have been proposed to function in the immune synapse
between T cells and antigen-presenting or other immune
cells, perhaps via homotypic interactions (1). In human and
murine cells, CD84, CD150, CD229, CD244, and NTB-A/
Ly-108 bind to and use at least two adaptor proteins: the
X-linked SLAM-associated protein SH2D1A, which is pre-
dominantly expressed in T, NK, and some B cells, and the
SLAM-associated protein–like adaptor EAT2, which appears
to account for CD150 family activity in other hematopoietic
cell lineages. In general, the expression of each of these re-
ceptor and adaptor molecules increases during lymphocyte
activation (2), suggesting that they modulate lymphocyte
effector functions. Indeed, recent studies indicate that
CD244 plays an inhibitory role during the cytotoxic re-
sponses of murine NK cells (3), whereas CD150 modulates
IL-4 production by murine T cells as well as the activation
of murine macrophages (4), and SH2D1A-deficient mice
demonstrate increased IFN-
 
  
 
production with defective IL-4
production by T cells as well as dysgammaglobulinemia
(5–7). In addition, at least during infection with lympho-
cytic choriomeningitis virus, SH2D1A-deficient mice are
unable to maintain long-term antiviral antibody responses in
a T cell–dependent fashion, reflecting defective memory B
cell and plasma cell formation, as well as defective germinal
center  formation (7). Thus, the CD150–SH2D1A system
likely modulates T-dependent immune responses, but the bi-
ological context(s) in which it predominantly functions re-
mains incompletely defined.
In humoral autoimmune diseases like lupus, hyperactivated
B cells spontaneously elaborate pathogenic, high titer,
high affinity autoantibodies, such as anti–double stranded
(ds)DNA, which mediates immune complex end-organ
diseases, such as glomerulonephritis (8). This process criti-
cally requires T cell help to promote class switching, and
presumably also to promote affinity maturation via a germinal
center reaction or similar T–B cell collaboration. Several
 
J.D. Hron and L. Caplan contributed equally to this work.
The online version of this article contains supplemental material.
Address correspondence to Stanford L. Peng, Washington University
School of Medicine, Campus Box 8045, CSRB 6617, 660 S. Euclid
Ave., St. Louis, MO 63110. Phone: (314) 747-3609; Fax: (314) 454-
1091; email: speng@im.wustl.edu 
SH2D1A Regulates Murine Lupus
 
262
target systems have been identified that likely participate in
and/or promote this process, including CD40-CD154,
types I and II IFNs, and BLys/BAFF, but several murine
and human studies suggest that these systems are insufficient
to explain fully the pathogenesis of lupus autoantibodies,
and/or that these systems are not the most proximal immune
aberrations during the development of the disease (8).
During ongoing studies to identify novel target genes in
lupus, we found that CD150-related molecules, as well as
SH2D1A, are up-regulated in the circulating lymphocytes
of lupus-prone, but not nonautoimmune, mice. Therefore,
we reasoned that SH2D1A-deficient mice could provide
an initial insight as to the importance of this system in the
pathogenesis of humoral autoimmunity. SH2D1A-defi-
cient animals were resistant to experimentally induced lu-
pus, but interestingly, these effects could not be attributed
to gross defects in T or B cells. Instead, SH2D1A defi-
ciency resulted in impaired humoral T-dependent humoral
immunity associated with defective germinal center re-
sponses. Thus, the CD150–SH2D1A system appears to
play a specific role in the elaboration of T-dependent hu-
moral autoimmunity, implicating molecules within this
family as both pathogenic and therapeutic targets in hu-
morally mediated immune diseases in general.
 
Materials and Methods
 
Mice.
 
SH2D1A-deficient (5) and WT mice of the 129 back-
ground, as well as C57BL/6, BALB/c, BXSB, and MRL/
 
  
 
(The
Jackson Laboratory) mice were maintained under specific patho-
gen-free conditions. All experiments were performed in compli-
ance with the relevant laws and institutional guidelines of the
Washington University School of Medicine.
 
CD150 and Ly-108 Quantification.
 
Peripheral blood leuko-
cytes were isolated via Ficoll-Paque density centrifugation (Am-
ersham Biosciences). RNA and cDNA were prepared and sub-
jected to real-time PCR as described previously (9), using
the  following gene-specific primers: CD150, 5
 
 
 
-AGCAGTA-
TCTCTAGGACCTTCAACCT and 5
 
 
 
-CCATGGACTCGA-
TTCTGAGGA; Ly108, 5
 
 
 
-TGCTGTCAGCAATTTGTCAG-
TCT and 5
 
 
 
-CATTCCAGGGTGGATTAGTTAGAAC. Rela-
tive mRNA abundance of each transcript was normalized against
tubulin (10).
 
Experimental Lupus Induction and Assessment.
 
To induce lu-
pus, 6–8-wk-old animals were injected with 0.5 ml pristane
(2,6,10,14-tetramethylpentadecane; ICN Biomedicals; refer-
ences 11 and 12). At the times indicated, assessments for serum
immunoglobulins, autoantibodies, renal immune deposits, and
glomerulonephritis were performed essentially as described previ-
ously (12–14).
 
Experimental Autoimmune Encephalomyelitis (EAE) Induction and
Assessment.
 
EAE was induced using the MOG
 
38-50 
 
peptide, sim-
ilar to a previously described protocol (15). In brief, on day 0
each animal received a subcutaneous injection of 300 
 
 
 
g peptide
in 0.3 ml PBS emulsified in an equal volume of complete Freund’s
adjuvant (Pierce Chemical Co.) with 1.2 mg 
 
Mycobacterium tuber-
culosis
 
 H37RA (Difco), as well as an intraperitoneal injection of
200 ng pertussis toxin in 0.2 ml PBS. On day 2, the animals were
given a second injection of 200 ng pertussis toxin in 0.2 ml PBS.
Animals were then examined daily for signs of EAE and scored
according to the following standard clinical scale: 0, no disease; 1,
tail paralysis; 2, hind limb weakness; 3, hind limb paralysis; 4,
hind- and fore-limb paralysis; 5, moribund or dead.
 
Immunizations.
 
Naive animals were injected intraperitoneally
with 50 
 
 
 
g TNP-CGG (T-dependent) or TNP-Ficoll (T-inde-
pendent) in 0.5 ml PBS. Sera were collected weekly thereafter
for the assessment of hapten-specific antibody by ELISA using
TNP(3)-BSA and TNP(34)-BSA (Biosearch), and IgG isotype-
specific antibodies (Southern Biotechnology Associates, Inc.).
Germinal centers were identified on 5-
 
 
 
M OCT-embedded fro-
zen spleen sections using FITC-conjugated peanut agglutinin
(PNA) and visualization by fluorescence microscopy.
 
Online Supplemental Material.
 
Online materials include Fig.
S1, which displays the real-time PCR data of CD150 family
member expression in the peripheral blood leukocytes of lupus-
prone mice, and Fig. S2, which displays the serum total Ig isotype
data for pristane-treated SH2D1A WT and KO mice. Figs. S1
and S2 are available at http://www.jem.org/cgi/content/full/
jem.20040526/DC1.
 
Results and Discussion
 
SH2D1A-deficient Mice Are Protected from Experimentally
Induced Lupus.
 
Using an ongoing microarray-based ap-
proach (9), we have found that CD150 family members
are elevated in lymphocytes from lupus-prone (MRL/
 
 
 
,
BXSB, and pristine-treated 129), but not nonautoimmune
(BALB/c, C57BL/6, and saline-treated 129), mouse strains
(Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20040526/DC1, and unpublished data). Because
many receptors of the CD150 family signal via SH2D1A
(1), these findings prompted us to examine the role specifi-
cally of SH2D1A in lupus. Therefore, we tested the ability
of SH2D1A-deficient (KO) mice to develop lupus using an
experimentally induced model, pristane. Treated WT ani-
mals developed hypergammaglobulinemia of the IgG1 and
IgG2a isotypes, which was evident as early as 6 wk after
administration (Fig. S2, available at http://www.jem.
org/cgi/content/full/jem.20040526/DC1, and unpublished
data; P 
 
  
 
0.01 for both isotypes comparing pristane- to
PBS-treated WT animals). In addition, pristane-treated
WT animals developed relatively high titers (
 
 
 
1:640) of
antinuclear antibodies (ANAs), which were evident in 10%
of the animals as early as 10 wk after pristane administra-
tion, and 100% of the animals by 5 mo (Fig. 1, A and B).
They also developed both anti–single stranded (ss)DNA
and anti-dsDNA specificities: 81% (13 out of 16) of pris-
tane-treated WT animals were positive for both anti-
ssDNA and anti-dsDNA IgG antibodies, 12 of which (92%)
were positive by 
 
Crithidia lucillae
 
 immunofluorescence (P 
 
 
 
0.0001 comparing pristane-treated to PBS-treated WT ani-
mals for both specificities). Interestingly, PBS-treated WT
animals developed perceptibly abnormal rheumatoid factor
activity, at least when compared with unmanipulated
BALB/c animals that were used as reference sera; nonethe-
less, this activity was also increased by pristane (P 
 
  
 
0.02
comparing pristane-treated to PBS-treated WT animals).
Finally, pristane-treated WT animals reliably developed re-
nal disease, as evidenced by renal immune deposits and a 
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diffuse proliferative glomeulonephritis (Fig. 1 D and Table
I). Thus, pristane-treated, but not PBS-treated, WT ani-
mals developed a clear lupus-like syndrome, including
hypergammaglobulinemia, ANAs, anti–dsDNA antibodies,
renal immune deposits, and glomerulonephritis.
In contrast, KO mice were significantly protected from
lupus. Although some pristane-treated KO animals devel-
oped hypergammaglobulinemia of the IgG1 isotype, the
majority of animals failed to do so such that although the
difference between pristane-treated WT and KO animals
was mildly significant (P 
 
  
 
0.05), the difference between
PBS- and pristane-treated KO animals was not (P 
 
  
 
NS;
Fig. S1). More impressively, SH2D1A was critical for the
ability of pristane to induce hyper-IgG2a (P 
 
  
 
0.001 com-
paring pristane-treated WT and KO animals); however,
there was a significant difference between IgG2a levels in
PBS-treated WT and KO animals (P 
 
  
 
0.01), suggesting
that SH2D1A might be required for the spontaneous (non-
induced) generation of conventional IgG2a.
KO animals were protected from the development of
autoantibodies (Fig. 1, A–C), including ANA (P 
 
  
 
0.0001
comparing pristane-treated WT and KO animals) and
anti-DNA (P 
 
  
 
0.001 comparing pristane-treated WT
and KO animals for both anti-ssDNA and anti-dsDNA).
Although some pristane-treated KO animals developed
detectable anti-ssDNA IgG (3 out of 16 
 
  
 
19%), these ap-
peared to be of low affinity because the same sera failed to
test positive in an anti-dsDNA ELISA or by 
 
Crithidia
 
 im-
munofluorescence. Interestingly, pristane significantly in-
creased rheumatoid factor activity in KO animals (P 
 
 
 
0.01 comparing pristane-treated to PBS-treated KO ani-
mals), although their activities were modestly lower than
their pristane-treated WT counterparts (P 
 
  
 
0.10 compar-
ing pristane-treated WT and KO animals). Finally, KO
animals were fully protected from the development of sig-
nificant renal disease, failing to develop significant im-
mune deposits or glomerular lesions (Fig. 1 D and Table
I), in contrast to their WT counterparts (P 
 
  
 
0.0001). In
addition, KO animals failed to develop significant pro-
teinuria, in contrast to their WT counterparts (10 out of
12 WT vs. 0 out of 13 KO animals developed proteinuria
 
 
 
30 mg/ml; P 
 
  
 
0.0001). Thus, SH2D1A deficiency
protects against murine lupus, as judged by hypergamma-
globulinemia, ANAs, anti-DNA, renal immune deposits,
and glomerulonephritis.
 
SH2D1A-deficient Mice Are Susceptible to EAE.
 
Be-
cause the pathogenesis of lupus heavily requires autoreac-
tive Th cells (8), the KO animals may have been protected
from lupus due to severely defective T cell function. To
determine if an autoimmune-related Th cell effector func-
tion was defective in KO mice, we tested their ability to
develop EAE in response to the MOG
 
38-50 
 
peptide, a Th1
cell–related, T cell–mediated disease (16). Surprisingly, KO
animals were, if anything, more susceptible to EAE (Fig. 2,
e.g., at days 13–15; P 
 
  
 
0.01). Thus, at least for this T-depen-
dent autoimmune disease, SH2D1A is dispensable and is
likely protective, suggesting that the protection of KO ani-
mals from experimental lupus cannot be explained by
grossly defective T cell function. Indeed, KO T cells have
been reported to produce increased amounts of IFN-
 
 
 
, an
effect that could exacerbate a Th1 cell–mediated cellular
autoimmune syndrome (5, 6).
Figure 1. SH2D1A-deficient mice
are protected from experimentally in-
duced lupus. 6–8-wk-old SH2D1A-
deficient (KO) or -sufficient (WT) mice
were injected intraperitoneally with 0.5
ml pristane (P) or PBS (S, saline). (A and
B) 5 mo later, sera were assayed and ti-
tered for the presence of ANAs (ANA).
The representative ANA fluorescence
pattern of a WT versus KO serum as-
sayed at a 1:40 dilution is shown in B.
(C) Rheumatoid factor and anti-ssDNA
and anti-dsDNA titers were determined
by ELISA. Specimens positive by
Crithidia lucillae immunofluorescence are
indicated in the anti-dsDNA graph in
red. n   4, 16, 4, and 18 for WT   P,
WT   S, KO   P, and KO   S, re-
spectively. Dotted lines indicate thresholds
for positivity, as determined by three
standard deviations above the mean of
nonautoimmune BALB/c mice. (D) Rep-
resentative  renal histology (H/E) and
glomerular IgG deposition (IgG) of WT
versus KO animals 15 wk after treatment
with pristane. Note the development of
mesangila wall thickening and glomerular
hypercellularity associated with IgG
deposition in WT, but not KO, kidneys. 
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SH2D1A-deficient Mice Mount Normal T-independent, But
Not T-dependent, Humoral Immune Responses.
 
In contrast,
lupus is hallmarked by uncontrolled humoral, not cellular,
autoimmunity. Therefore, we turned to model immuniza-
tion systems to understand further the role of SH2D1A in
antibody production, and examined responses to two con-
ventional antigens, the T-dependent TNP-CGG and the
T-independent TNP-Ficoll (Fig. 3 A). KO animals were
largely impaired in their ability to generate IgG1 antihapten
antibodies in response to TNP-CGG (P 
 
  
 
0.001 compar-
ing WT to KO at all time points tested), but only a minor-
ity (30–40%) of KO animals were able to develop IgG3
antihapten antibodies with activities that appeared
comparable to WT animals, at least as judged by OD val-
ues (Fig. 3 A; P 
 
  
 
0.05 comparing WT to KO at 28 d). In
contrast, KO animals were not at all impaired in their abil-
ity to generate antihapten antibodies of any IgG isotype in
response to TNP-Ficoll immunization (Fig. 3 and unpub-
lished data). Such findings, particularly with TNP-Ficoll,
strongly suggest that intrinsic B cell functions are largely
preserved in the absence of SH2D1A; rather, SH2D1A ap-
peared to be required for T-dependent B cell antibody re-
sponses. Indeed, KO antibodies were of lower affinity than
WT, at least as judged by the ratio of ELISA activities
against TNP(3)-BSA and TNP(34)-BSA (Fig. 3 B). Thus,
although KO animals could mount some detectable class-
switched antibody to a T-dependent antigen, they did not
appear to be capable of proper affinity maturation.
Because affinity maturation in B cells is generally
thought to arise in T-dependent germinal centers (17), we
examined immunized SH2D1A-deficient mice for the
presence of germinal centers (Fig. 3 C). As judged by
(PNA) staining, KO animals were significantly impaired in
the formation of germinal centers. Whereas WT spleens
generally developed 10 
 
  
 
3 germinal centers per high
powered field, KO animals developed only 0.1 
 
  
 
0.2 (P 
 
 
 
0.0001, 
 
n 
 
  
 
6 of each genotype tested). A similar difference
was seen in pristane-treated animals (Fig. 3 D), where WT
spleens generally contained 3 
 
  
 
0.3 PNA
 
  
 
germinal centers
per high powered field that were generally larger than their
TNP-CGG–immunized counterparts, whereas KO spleens
contained no (0 
 
  
 
0) detectable germinal centers (P 
 
 
 
0.0001, 
 
n 
 
  
 
4 of each genotype tested). Thus, SH2D1A
deficiency is associated with defective T-dependent anti-
body response and germinal center formation. Interest-
ingly, KO CD4
 
  
 
T cells could generate levels of CXCR3,
CXCR5, CCR5, ICOS, and CD154 comparable to their
WT counterparts (unpublished data), suggesting that per-
haps the homotypic interactions between the CD150 fam-
ily members themselves, as has been proposed to mediate
and/or promote lymphocyte collaboration (1), were re-
sponsible for this phenotype.
 
The Role of the CD150–SH2D1A System in Humoral Im-
munity.
 
Interestingly, a recent study has suggested that
SH2D1A is not required for early antigen-specific antibod-
ies, but is required for the maintenance of long-term anti-
bodies, at least in a virus infection model (7). In contrast,
our data indicate that T-dependent antibody responses are
impaired in KO mice, even at early time points (Fig. 3 A),
whereas T-independent antibody responses are not affected
and can actually be maintained for 
 
 
 
8 wk after initial im-
munization (Fig. 3 A), which is clearly longer than the 14–
30-d time points at which a difference in antiviral titers
between WT and KO animals were observed (7). These
observations could be reconciled by considering that much
of the early (
 
 
 
21 d) antibody during viral infection reflects
 
Table I.
 
Renal Disease in Pristane-treated SH2D1A Mice
 
Genotype Treatment
Time
examined
 
a
 
Ig
deposits
 
b
 
Glomerular
disease
 
b
 
WT Pristane 15
 
      
 
WT Pristane 15
 
       
 
WT Pristane 15
 
       
 
WT Pristane 15
 
       
 
WT Pristane 15
 
     
 
KO Pristane 15
 
  
 
KO Pristane 15
 
  
 
KO Pristane 15
 
  
 
KO Pristane 15
 
  
 
KO Pristane 15
 
  
 
WT PBS 25
 
  
 
WT PBS 25
 
  
 
WT Pristane 25
 
        
 
WT Pristane 25
 
        
 
WT Pristane 25
 
        
 
KO Pristane 25
 
  
 
KO Pristane 25
 
  
 
KO Pristane 25
 
  
 
a
 
Weeks after treatment administration.
 
b
 
Scored on a 1
 
  
 
to 4
 
  
 
basis as in references 13 and 14.
Figure 2. SH2D1A-deficient mice are susceptible to experimental au-
toimmune EAE. EAE was induced in 5–6-wk-old SH2D1A-deficient
(KO) or -sufficient (WT) mice using the MOG38-50 peptide. Clinical
score was determined daily on each animal. Data points indicate means  
standard deviations. 
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T-independent B cell activation, whereas longer-term
(
 
 
 
21 d) antibody reflects the additional contribution of
high titer, high affinity antibodies generated after T cell
help and germinal center reaction (18). Thus, perhaps the
early antiviral immunity seen in KO animals reflects T-inde-
pendent activation, whereas the apparent defect in long-
term antibody responses reflects an inability to generate
T-dependent immunity in addition to the T-independent
response, which alone would have a relatively low activity
due to the lack of affinity maturation. Therefore, continued
investigation into the role of SH2D1A in different antigen-
specific antibody responses is warranted.
Although SH2D1A does not map to any known lupus
susceptibility locus (19), the CD150 family are candidate
genes for Sle1b, a chromosome 1 lupus susceptibility locus
in the New Zealand murine lupus model, where it segre-
gates with a higher penetrance of autoantibodies and hy-
pergammaglobulinemia, and is associated with poly-
morphisms in and/or dysregulated expression of various
CD150 family members, including Ly-108, CD229,
CD48, and CD84 (20–22). Given the present findings,
dysregulation of the CD150–SH2D1A system in lupus may
therefore promote pathogenic T-dependent B cell reac-
tions, such as the germinal center reaction, leading to
heightened autoantibody production and subsequent im-
mune complex disease. As such, it will be of significant in-
terest to explore the role of SH2D1A and the CD150 mol-
ecules in other murine autoimmune models, particularly
the New Zealand strains, as well as human lupus.
At the same time, these findings suggest that the
CD150–SH2D1A system may play a more general role in
several types of pathogenic antibody responses, such as
those that might require high affinity, germinal center–
dependent antibodies, including humoral autoimmune
syndromes like myasthenia gravis, or other inappropriate
humoral immune diseases like allergies. In this sense it is
worth reiterating that SH2D1A deficiency does not seem
to significantly impair gross intrinsic T or B cell function,
but rather an effector function that specifically requires
their cooperation/collaboration. Thus, the CD150–SH2D1A
system may prove to be a uniquely specific and valuable
target in the pathogenesis and therapy of humorally medi-
ated inflammatory disorders.
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